A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans
- PMID: 17322917
- DOI: 10.1038/sj.onc.1210199
A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans
Abstract
Cancer biology finds itself in a post-genomic era and the hopes of using inherited genetic variants to improve prevention and treatment strategies are widespread. One of the largest types of inherited genetic variation is the single nucleotide polymorphism (SNP), of which there are at least 4.5 million. The challenge now becomes how to discover which polymorphisms alter cancer in humans and how to begin to understand their mechanism of action. In this report, a series of recent publications will be reviewed that have studied a polymorphism in the p53 tumor suppressor pathway, MDM2 SNP309. These reports have lent insights into how germline genetic variants of the p53 pathway could interact with gender, environmental stresses and tumor genetics to affect cancer in humans. Importantly, these observations have also exposed potential nodes of intervention, which could prove valuable in both the prevention and treatment of this disease in humans.
Similar articles
-
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.Cell. 2004 Nov 24;119(5):591-602. doi: 10.1016/j.cell.2004.11.022. Cell. 2004. PMID: 15550242
-
A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.Cancer Res. 2007 Mar 15;67(6):2757-65. doi: 10.1158/0008-5472.CAN-06-2656. Cancer Res. 2007. PMID: 17363597
-
Shaping genetic alterations in human cancer: the p53 mutation paradigm.Cancer Cell. 2007 Oct;12(4):303-12. doi: 10.1016/j.ccr.2007.10.001. Cancer Cell. 2007. PMID: 17936556 Review.
-
Association of breast cancer outcome with status of p53 and MDM2 SNP309.J Natl Cancer Inst. 2006 Jul 5;98(13):911-9. doi: 10.1093/jnci/djj245. J Natl Cancer Inst. 2006. PMID: 16818855
-
The p53 mutation "gradient effect" and its clinical implications.J Cell Physiol. 2007 Nov;213(2):370-3. doi: 10.1002/jcp.21217. J Cell Physiol. 2007. PMID: 17671971 Review.
Cited by
-
Np9, a cellular protein of retroviral ancestry restricted to human, chimpanzee and gorilla, binds and regulates ubiquitin ligase MDM2.Cell Cycle. 2015;14(16):2619-33. doi: 10.1080/15384101.2015.1064565. Epub 2015 Jun 23. Cell Cycle. 2015. PMID: 26103464 Free PMC article.
-
Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.Tumour Biol. 2013 Dec;34(6):3721-9. doi: 10.1007/s13277-013-0956-z. Epub 2013 Aug 3. Tumour Biol. 2013. PMID: 23912932
-
Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.Oncogenesis. 2016 Feb 29;5(2):e205. doi: 10.1038/oncsis.2016.15. Oncogenesis. 2016. PMID: 26926790 Free PMC article.
-
Alterations of the TP53 gene in gastric and esophageal carcinogenesis.J Biomed Biotechnol. 2012;2012:891961. doi: 10.1155/2012/891961. Epub 2012 Aug 7. J Biomed Biotechnol. 2012. PMID: 22919278 Free PMC article. Review.
-
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.BMC Cancer. 2010 Feb 23;10:57. doi: 10.1186/1471-2407-10-57. BMC Cancer. 2010. PMID: 20178585 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous